High dose intensity doxorubicin in aggressive non-Hodgkin's lymphoma: a literature-based meta-analysis

被引：12
作者：
Azim, H. A. [2 ]
Santoro, L. [3 ]
Bociek, R. G. [4 ]
Gandini, S. [3 ]
Malek, R. A. [2 ]
Azim, H. A., Jr. [1 ]
机构：
[1] Cairo Univ, Natl Canc Inst, Dept Med Oncol, Cairo, Egypt
[2] Cairo Univ Hosp, Dept Clin Oncol, Cairo, Egypt
[3] European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy
[4] Univ Nebraska, Med Ctr, Dept Internal Med, Hematol Oncol Sect, Omaha, NE USA
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷 / 05期
关键词：
chemotherapy; CHOP; dose intensity; doxorubicin; non-Hodgkin's lymphoma; CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; 3-WEEKLY CHOP CHEMOTHERAPY; STANDARD REGIMEN CHOP; ELDERLY-PATIENTS; INTERMEDIATE-GRADE; MACOP-B; YOUNG-PATIENTS; CELL LYMPHOMA; PHASE-III;
D O I：
10.1093/annonc/mdp425
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Methods: A Medline and Cochrane library search was carried out using the search terms 'CHOP', 'lymphoma' and 'randomized trials'. Eligible trials had CHOP as a control arm and any regimen administering doxorubicin at a higher DI (16.6 mg/m(2)/week) as the investigational arm. Pooling of data was carried out using the mixed effect model. Results: Eight trials were eligible. Patients receiving DI doxorubicin-based regimens had a significantly better overall survival [summary hazard ratio (SHR) 0.82; 95% confidence interval (CI) 0.71-0.96], event-free survival (SHR 0.86; 95% CI 0.75-0.99) and higher complete response rate (summary odds ratio 0.91; 95% CI 0.67-0.97). Conclusion: High DI doxorubicin based should be considered in patients with aggressive NHL.
引用
收藏
页码：1064 / 1071
页数：8
相关论文
共 30 条
[1]  
Armitage JO, 2006, ONCOLOGY-NY, V20, P231
[2]   Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas [J].
Cheson, BD ;
Horning, SJ ;
Coiffier, B ;
Shipp, MA ;
Fisher, RI ;
Connors, JM ;
Lister, TA ;
Vose, J ;
Grillo-López, A ;
Hagenbeek, A ;
Cabanillas, F ;
Klippensten, D ;
Hiddemann, W ;
Castellino, R ;
Harris, NL ;
Armitage, JO ;
Carter, W ;
Hoppe, R ;
Canellos, GP .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1244-1253
[3]  
Clarke M.J., 2001, Systematic review in health care, mata-analysis in context, V1st, P109
[4]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[5]   RANDOMIZED COMPARISON OF MACOP-B WITH CHOP IN PATIENTS WITH INTERMEDIATE-GRADE NON-HODGKINS-LYMPHOMA [J].
COOPER, IA ;
WOLF, MM ;
ROBERTSON, TI ;
FOX, RM ;
MATTHEWS, JP ;
STONE, JM ;
DING, JC ;
DART, G ;
MATTHEWS, J ;
FIRKIN, FC ;
LOWENTHAL, RM ;
IRONSIDE, P .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (04) :769-778
[6]   COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (14) :1002-1006
[7]   A PHASE-III COMPARISON OF CHOP VS M-BACOD VS PROMACE-CYTABOM VS MACOP-B IN PATIENTS WITH INTERMEDIATE-GRADE OR HIGH-GRADE NON-HODGKINS-LYMPHOMA - RESULTS OF SWOG-8516 (INTERGROUP 0067), THE NATIONAL HIGH-PRIORITY LYMPHOMA STUDY [J].
FISHER, RI ;
GAYNOR, ER ;
DAHLBERG, S ;
OKEN, MM ;
GROGAN, TM ;
MIZE, EM ;
GLICK, JH ;
COLTMAN, CA ;
MILLER, TP .
ANNALS OF ONCOLOGY, 1994, 5 :S91-S95
[8]   PHASE-III STUDY OF BCOP V CHOP IN UNFAVORABLE CATEGORIES OF MALIGNANT-LYMPHOMA - A SOUTHEASTERN CANCER STUDY-GROUP TRIAL [J].
GAMS, RA ;
RAINEY, M ;
DANDY, M ;
BARTOLUCCI, AA ;
SILBERMAN, H ;
OMURA, G .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (09) :1188-1195
[9]  
GREENLAND S, 1987, EPIDEMIOL REV, V9, P1
[10]   Quantifying heterogeneity in a meta-analysis [J].
Higgins, JPT ;
Thompson, SG .
STATISTICS IN MEDICINE, 2002, 21 (11) :1539-1558
123